Lista de obras - Charalabos-Markos Dintsios

A distorted picture of IQWiG methodology

artículo científico publicado en 2010

Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany.

artículo científico publicado en 2014

Arbitration Board Setting Reimbursement Amounts for Pharmaceutical Innovations in Germany When Price Negations between Payers and Manufacturers Fail: An Empirical Analysis of 5 Years' Experience.

artículo científico publicado en 2016

Coated stents to prevent restenosis in coronary heart disease ⬇️

artículo científico publicado el 2 de noviembre de 2005

Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany - are additional data requirements by the Federal Joint Committee justified?

artículo científico publicado en 2016

Determinants of Orphan Drug Prices in Germany

artículo científico publicado en 2020

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree

artículo científico publicado en 2019

Direct costs in impaired glucose regulation: results from the population-based Heinz Nixdorf Recall study

artículo científico publicado en 2016

Drug-eluting stents vs. coronary artery bypass-grafting in coronary heart disease

artículo científico publicado en 2008

Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation.

artículo científico publicado en 2013

Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany.

artículo científico publicado en 2010

Effect of person-centred care on antipsychotic drug use in nursing homes (EPCentCare): study protocol for a cluster-randomised controlled trial

artículo científico publicado en 2015

Failure due to formal reasons within German benefit assessment of medicinal products: the dilemma between marketing authorization and HTA

scientific article published on 20 February 2020

Implementation of a Multicomponent intervention to Prevent Physical Restraints In Nursing home residenTs (IMPRINT): study protocol for a cluster-randomised controlled trial

artículo científico publicado en 2015

Information on ethical issues in health technology assessment: how and where to find them

article

Integrating patients' views into health technology assessment: Analytic hierarchy process (AHP) as a method to elicit patient preferences

artículo científico

Laparoscopic vs. open appendectomy: systematic review of medical efficacy and health economic analysis ⬇️

artículo científico publicado el 29 de enero de 2007

Letter to the editor of the Journal of Affective Disorders: Supporting the guideline's quest for real direct costs of depression care

artículo científico publicado en 2016

Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany.

artículo científico publicado en 2018

Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany.

artículo científico publicado en 2014

Patientenberichtete und patientengewichtete Endpunkte in der Augenheilkunde

artículo científico publicado en 2009

Predictors of negotiated prices for new drugs in Germany

scientific article published on 25 May 2020

Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment.

artículo científico publicado en 2016

Promoting physical activity in low back pain patients: six months follow-up of a randomised controlled trial comparing a multicomponent intervention with a low intensity intervention

artículo científico publicado en 2016

Quantified patient preferences for lifestyle intervention programs for diabetes prevention-a protocol for a systematic review

scholarly article by Charalabos-Markos Dintsios et al published 29 November 2018 in Systematic Reviews

Questioning patient subgroups for benefit assessment: challenging the German Gemeinsamer Bundesausschuss approach.

artículo científico publicado en 2014

Re: "Early benefit assessment of new drugs in Germany--results from 2011 to 2012" [Health Policy 116 (2-3) (2014) 147-153].

artículo científico publicado en 2014

Re: Patient and physician preferences for the treatment of chronic hepatitis C virus infections: does the perspective matter? (Eur J Gastroenterol Hepatol 2015, 27:1063-1068).

artículo científico publicado en 2016

Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing?

artículo científico publicado en 2011

Relevance of Variations in the Opposing Dentition for the Functionality of Fixed and Removable Partial Dentures: A Systematic Review ⬇️

artículo científico publicado el 4 de noviembre de 2012

Some essential clarifications: IQWiG comments on two critiques of the efficiency frontier approach

scientific article published on 01 October 2010

Subgroups in the early benefit assessment of pharmaceuticals: a methodical review

artículo científico publicado en 2015

The impact of HTA reports on health policy: a systematic review.

artículo científico publicado en 2005

Using the analytic hierarchy process to elicit patient preferences: prioritizing multiple outcome measures of antidepressant drug treatment.

artículo científico publicado en 2012

When suddenly the evaluation became a validation

artículo científico publicado en 2015

[Checklist for the Development and Assessment of Cost-of-Illness Studies]

artículo científico publicado en 2017

[Health-Related Quality of Life in the Context of Early Benefit Assessment of Drugs According to § 35a of the German Social Code Book V: A Challenging Endpoint for all the Involved Stakeholders].

artículo científico publicado en 2016

[Health-economic modeling on the use of drug-eluting stents versus coronary artery bypass graft surgery in coronary heart disease].

artículo científico publicado en 2009

[IQWiG's methods for the cost-benefit assessment : Comparison with an international reference scenario]

scientific article published on 01 June 2010

[Intravascular brachytherapy for peripheral arterial occlusive disease: systematic review of medical efficacy and health economic modelling]

artículo científico publicado en 2009

[Methods of health economic evaluation for health services research]

scientific article published on 23 September 2010

[Patient participation in defining and assigning importance to treatment outcomes--status quo and potential developments]

scientific article published on 01 January 2008

Lista de obras de Charalabos-Markos Dintsios

A distorted picture of IQWiG methodology

Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany.

Arbitration Board Setting Reimbursement Amounts for Pharmaceutical Innovations in Germany When Price Negations between Payers and Manufacturers Fail: An Empirical Analysis of 5 Years' Experience.

Coated stents to prevent restenosis in coronary heart disease ⬇️

Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany - are additional data requirements by the Federal Joint Committee justified?

Determinants of Orphan Drug Prices in Germany

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree

Direct costs in impaired glucose regulation: results from the population-based Heinz Nixdorf Recall study

Drug-eluting stents vs. coronary artery bypass-grafting in coronary heart disease

Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation.

Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany.

Effect of person-centred care on antipsychotic drug use in nursing homes (EPCentCare): study protocol for a cluster-randomised controlled trial

Failure due to formal reasons within German benefit assessment of medicinal products: the dilemma between marketing authorization and HTA

Implementation of a Multicomponent intervention to Prevent Physical Restraints In Nursing home residenTs (IMPRINT): study protocol for a cluster-randomised controlled trial

Information on ethical issues in health technology assessment: how and where to find them

Integrating patients' views into health technology assessment: Analytic hierarchy process (AHP) as a method to elicit patient preferences

Laparoscopic vs. open appendectomy: systematic review of medical efficacy and health economic analysis ⬇️

Letter to the editor of the Journal of Affective Disorders: Supporting the guideline's quest for real direct costs of depression care

Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany.

Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany.

Patientenberichtete und patientengewichtete Endpunkte in der Augenheilkunde

Predictors of negotiated prices for new drugs in Germany

Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment.

Promoting physical activity in low back pain patients: six months follow-up of a randomised controlled trial comparing a multicomponent intervention with a low intensity intervention

Quantified patient preferences for lifestyle intervention programs for diabetes prevention-a protocol for a systematic review

Questioning patient subgroups for benefit assessment: challenging the German Gemeinsamer Bundesausschuss approach.

Re: "Early benefit assessment of new drugs in Germany--results from 2011 to 2012" [Health Policy 116 (2-3) (2014) 147-153].

Re: Patient and physician preferences for the treatment of chronic hepatitis C virus infections: does the perspective matter? (Eur J Gastroenterol Hepatol 2015, 27:1063-1068).

Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing?

Relevance of Variations in the Opposing Dentition for the Functionality of Fixed and Removable Partial Dentures: A Systematic Review ⬇️

Some essential clarifications: IQWiG comments on two critiques of the efficiency frontier approach

Subgroups in the early benefit assessment of pharmaceuticals: a methodical review

The impact of HTA reports on health policy: a systematic review.

Using the analytic hierarchy process to elicit patient preferences: prioritizing multiple outcome measures of antidepressant drug treatment.

When suddenly the evaluation became a validation

[Checklist for the Development and Assessment of Cost-of-Illness Studies]

[Health-Related Quality of Life in the Context of Early Benefit Assessment of Drugs According to § 35a of the German Social Code Book V: A Challenging Endpoint for all the Involved Stakeholders].

[Health-economic modeling on the use of drug-eluting stents versus coronary artery bypass graft surgery in coronary heart disease].

[IQWiG's methods for the cost-benefit assessment : Comparison with an international reference scenario]

[Intravascular brachytherapy for peripheral arterial occlusive disease: systematic review of medical efficacy and health economic modelling]

[Methods of health economic evaluation for health services research]

[Patient participation in defining and assigning importance to treatment outcomes--status quo and potential developments]